Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.
Where this comes from
- Record sourced from PubMed, PMID 28505305.
- Also identified by DOI 10.1093/cid/cix441 and PMC identifier 6248462.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.
Medical subject headings
- Anemia, Sickle Cell
- Antiviral Agents
- Benzimidazoles
- Fluorenes
- Hepatitis C, Chronic
- Sofosbuvir